Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma

Transcriptomics and Epigenetics Analysis for Biomarkers Identification Involved in Drug-resistance Mechanisms of Multiple Myeloma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05888636

Acronym

TEDROMM

Enrollment

200

Registered

2023-06-05

Start date

2019-06-18

Completion date

2024-12-31

Last updated

2024-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

Multiple Myeloma (MM) is the more common hematological neoplastic disease second only to Hodgkin lymphoma. In MM patients, mutated genes are mainly KRAS (23%), NRAS (20%), FAM46C (11%), DIS3 (11%) e TP53 (8%). Epigenetics studies suggested that Changes in histone modifications and DNA methylation pattern, as well as non-coding RNAs (miRNAs) expression are involved in MM development. In particular, it has been shown that the aberrant expression of different miRNAs could discriminate healthy from ill patients. Unfortunately, the main critical issue for an effective treatment of MM is the intrinsic or acquired resistance to pharmacological treatments, due also to a plasmacellular clonal heterogeneity. The prospective study will involve a patient cohort with MGUS, MM smouldering and MM, with the aim to characterize different transcriptional and epigenetic features, also including miRNAs, among MM cells susceptible or resistant to conventional therapies. The final goal is to identify new prognostic and predictive biomarkers that could be used as therapeutic tools to improve clinical targeted therapies.

Interventions

OTHERChIP-seq, NGS, ATAC-seq

Bone narrow sampling

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

\- Compare Transcriptomics and epigenetic profile

Exclusion criteria

* No

Design outcomes

Primary

Measure	Time frame	Description
Transcriptomics variations in treated and non-treated MGUS, MM smouldering and syntomatic MM samples	12 months	Characterize genetic/epigenetic profile of cells resistant to the treatment sampled from MM patients before and after treatement.
Epigenetics variations in treated and non-treated MGUS, MM smouldering and syntomatic MM samples	12 months	Quantify genetic/epigenetic profile of cells resistant to the treatment sampled from MM patients before and after treatement.

Countries

Italy

Contacts

Primary ContactMaurizio Fanciulli, PhD

maurizio.fanciulli@ifo.it*39 06 52662800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026